IMAGING INNOVATIONS WEBINAR

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Technical Advancements in Clinical Learning- What’s New in 2021 Revolutionizing Precision Medicine One Lesion at a Time
Automated Evaluation of Disease on 68Ga-DOTATATE PET/CT Images for Long-term Lesion Tracking on 177Lu-DOTATATE Therapy
RALEIGH, N.C., June 9, 2022 /PRNewswire/ — Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partner program designed to move clinical AI/ML innovation to the front lines of healthcare. The Collaborative will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.
“Imaging biomarkers to better evaluate and predict treatment response for complex diseases.” Company Presentation Theater 2 Wednesday, June 15, 2022 4:00 pm- 4:15 pm ( PDT)
Find out more about AIQ Solutions technologies at kiosk IH22!
AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy.
Stop by our booth #923
Immuno-Oncology 360 2022 March 16-18, 2022 New York Marriott Brooklyn Bridge
AIQ Solutions will be attending J.P. Morgan 39th Annual Healthcare Conference from January 11th through January 15th, 2021 in a virtual format. Request a meeting to learn more about AIQ Solutions and our treatment response quantification and prediction technology.